We appreciate the comments of Hindié 1 and Goel et al 2 in their letters to the editor in response to our recent article in Journal of Clinical Oncology titled "Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial." 3 Our study concerned the impact of lymphoscintigraphy (LSG) on the accuracy of surgical axillary staging with sentinel lymph node biopsy (SLNB) in early breast cancer in everyday practice. 3 Because the letters refer to quite different topics associated with the role of LSG for SLNB in patients with breast cancer, we will respond to each one separately.When SLNB was introduced to routine care, surgeons lacked familiarity with the challenging new technique and had different awareness of the need to avoid unnecessary trauma. In our opinion, the speed of the procedure, detection rate, and extent of surgical trauma are crucially dependent on the experience of the breast surgeon and, to a lesser extent, on preoperative imaging. 4 We thus believe that the findings from 2005, 5 as cited by Hindié, 1 do not apply to the contemporary clinical situation. Transcutaneous gamma probe hot-spot detection and dual-tracer marking are commonly available to determine the optimal incision site.